| INTRODUC TI ON
Gallbladder cancer (GBC) is the sixth common gastrointestinal cancer and the sixth cause of cancer-related death in China. 1 Although improvement in diagnosis and treatment of GBC, the majority of the patients are usually confirmed as metastatic GBC (mGBC). 2, 3 Due to the lymph node or distant metastasis of the disease, its five years' overall survival rate was merely 5%. 3, 4 Thus, it is urgent for us to clarify the mechanisms of GBC occurrence and progression and to explore the effective clinical biomarker to predict the prognosis of the individuals.
Emerging evidences showed that up to 20% of the malignancies were caused by chronic inflammation, 5 and cancer-related inflammation played a decisive role in tumorigenesis, malignant conversion, and distant metastasis of GBC. 6 Systemic inflammation triggered by chronic infection, smoking, drinking, and obesity contributed to oncogene activation and inhibition of tumor suppressor gene, leading to occurrence of the disease. Moreover, inflammatory microenvironment protected GBC cell to escape from immune surveillance and promoted the specific organic metastasis through the formation of pre-metastatic niche. 7 Thus, we speculate that circulating inflammatory biomarker may reflect progression and predict clinical outcome of the disease.
Recently, there were lots of studies reported association of circulating inflammatory immune cell ratio and albumin-to-fibrinogen ratio (AFR) and fibrinogen-to-pre-albumin ratio (FPR) and prognosis of gastric cancer, non-small-cell lung cancer, colorectal cancer, and GBC. [8] [9] [10] [11] [12] Zhang et al reported that FPR was a feasible prognostic biomarker in surgical stage II and III gastric cancer and it could precisely distinguish stage III patients who appeared to obviously benefit from adjuvant chemotherapy. 8 Pretreatment AFR was reported to be a clinical biomarker to predict clinical efficacy of surgical resection and adjuvant chemo-radiotherapy and to be a prognostic biomarker for non-small-cell lung cancer individuals. 9 According to GBC, circulating neutrophil-to-lymphocyte ratio (NLR) was closely related to poor prognosis of surgical GBC patient. 10 However, there is no study reported the prognostic roles of derived neutrophil-to-lymphocyte ratio (dNLR), lymphocyte-to-monocyte ratio (LMR), AFR, and FPR in mGBC, and the prognostic significance of them remain to be determined.
Therefore, we detected and calculated pretreatment circulating immune cell, Fib, Alb, pAlb, NLR, dNLR, platelet-to-lymphocyte ratio (PLR), LMR, AFR, and FPR and obtained the overall survival (OS) of them by means of three years' follow-up in 220 mGBC cases to investigate the prognostic values of them in predicting clinical outcome of the disease.
| MATERIAL S AND ME THODS
In our study, we collected eligible mGBC patients in accordance with the following inclusion and exclusion criteria. First of all, the selected patients were clinically confirmed as mGBC without acute Fib, fibrinogen; Alb, albumin; pre-Alb, pre-albumin; AFR, albumin-to-fibrinogen ratio; FPR, fibrinogen-to-pre-albumin ratio; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-tomonocyte ratio; OS, overall survival; score 0 means both CEA and dNLR were less than the cutoff values; score 1 means either CEA or dNLR was higher than the cutoff values; score 2 means both CEA and dNLR were higher than the cutoff values.
The baseline characteristics such as name, gender, age, status of drinking and smoking, hypertension, diabetes, and metastatic information were retrieved and collected from medical record of each individual. Two milliliter EDTA anticoagulation peripheral blood, serum, and plasma samples were collected between 7:00 am and 9:00 am from the each individual, respectively. The peripheral blood counting was detected by semiconductor laser flow cytometry and nucleic acid staining method using SYSMEX XS-500i (SYSMEX CORPORATION, Chuo-ku, Kobe, Hyogo, Japan) automatic blood analyzer, and the internal and extraval coefficient of variations (CVs) of the method were less than 5%.
Bromocresol green method, immunity transmission turbidity, and coagulation method were selected to detect serum Alb and pAlb, and plasma Fib, respectively. The ratios of NLR, dNLR (total white blood cell counting-lymphocyte/lymphocyte), PLR, LMR, FPR, and AFR were calculated according to the detection results.
We performed the three years' OS by retrieving medical record, telephone, and correspondent letter, OS was the first endpoint of the study, and the deadline of follow-up was May 2018. The time from the diagnosis date to death or alive until the deadline was presented as OS.
In order to further investigate the prognostic values of CEA and dNLR, we established a novel CEA-dNLR score replying on the two biomarkers. Both CEA and dNLR less or higher than the cutoff values were defined as CEA-dNLR zero and two score, respectively. Either CEA or dNLR higher than the cutoff values was defined as the score one.
In present study, the optimal cutoff values of PLR, NLR, dNLR, AFR, and FPR were obtained using X-tile software. Kaplan-Meier curve, log-rank test, univariable and multivariable Cox proportion regression models were used to investigate the associations between the ratios and clinical outcome of the patients. Hazard ratio (HR) and 95% confidential interval (CI) were selected to measure the strength between them. Time-dependent receiver operating characteristics (ROC) were used to compare the efficacies of the ratios for mGBC survival prediction. All statistics were conducted using R 3.5.0 and IBM SPSS statistics 22 software (IBM Corporation, Armonk, NY, USA), and P < 0.05 implied significance between the groups.
| RE SULTS
A total of 220 mGBC patients were included in the study, and the baseline characteristics were presented in Table 1 . As shown from the Figure 1 ).
There was no significant survival difference in the patients strati- adjusted HR = 1.57, 95% CI = 1.00-2.46) was significantly inferior to the patients with the low levels of those biomarkers ( Figure 2 and Table 2 ).
In our study, time (Table 3) , and AUC of CEA-dNLR score for predicting clinical outcome of mGBC patients was 0.756, and it was significantly higher F I G U R E 2 Kaplan-Meier curves of dNLR, LMR, FPR, and CEA-dNLR score in 220 mGBC patients. A, dNLR; B, LMR; C, FPR; D, CEA-dNLR score; dNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; FPR, fibrinogen-to-pre-albumin ratio; mGBC, metastatic gallbladder cancer TA B L E 2 Cox regression model analyses of prognostic factors for 3 years' OS within 220 metastatic gallbladder cancer patients by Cox regression model F I G U R E 3 Time-dependent receiver operating characteristics of dNLR and CEA-dNLR score in 220 mGBC patients. A, dNLR; B, CEAdNLR score; dNLR, derived neutrophil-to-lymphocyte ratio; mGBC, metastatic gallbladder cancer; AUC, area under the curve 
| D ISCUSS I ON
Gallbladder cancer was recognized as a complex disease causing by interaction of personal genetic predisposition and environmental factor such as substantial intake of alcohol and tobacco as well as chronic inflammation. 11 Persistent chronic inflammatory response triggered by these environmental exposures in the patients, contributed to constitutive activation of pro-inflammatory signaling pathways, promoted mutation of KRAS, BRAF, PIK3CA, and IDH1/2, 12-15 consequently leading to onset and metastasis of GBC.
In our study, we comprehensively investigated circulating inflammatory-related cell, protein, and ratios of them to determine the simple, economical, practical clinical biomarker to effectively predict the survival of mGBC patients. We found that pretreatment pAlb, LMR, CEA, dNLR, and FPR were significantly associated with clinical outcome of mGBC patients, indicating that all of them were independent prognostic factors for the disease. Moreover, we found that the predicted efficacy of dNLR was the highest between them, implying that dNLR was superior to the other inflammatory biomarkers to predict the survival of the patients. Additionally, survival of the patients harbored high CEA-dNLR score was significantly inferior to the cases with the low score, and cancer-death risk of the patient with the score two and one was approximately twofold comparing to the score one and zero patients, respectively, the survival predicted AUC of the score was significantly higher than CEA and dNLR. These results suggested that a novel CEA-dNLR score was an independent prognostic factor for mGBC patients, and it was superior to the other inflammatory biomarkers to predict 3 years' OS of the patient.
Till now, several studies reported the association of inflammatory-related biomarker with clinical outcome of GBC. [16] [17] [18] However, the controversial results were observed between circulating ratio of peripheral blood cell and survival of the disease. 16, 17 In our study, we confirmed that the pAlb, dNLR, PLR, LMR, and FPR were independent prognostic factors for mGBC, and we found that dNLR was superior to PLR, LMR, and FPR to precisely predict prognosis of the disease. Neutrophil and monocyte are the main components of circulating leukocyte, and tumor-associated macrophage derived from monocytic precursors is recruited at the tumor site by CCL2/MCP-1 and EGF. 19, 20 Tumor-associated neutrophil and macrophage are important infiltrated components within mGBC patients, there are all Fib interacted with several growth factors to promote invasion and metastasis of GBC cell, leading to a poor survival of the patients.
27
This study is the first time for us to construct CEA-dNLR score and to investigate the predictive and prognostic roles of AFR, FPR, and the score in mGBC patients. Moreover, pAlb, LMR, dNLR, and FPR were reliable, economical, and practical biomarkers to predict the prognosis of mGBC, and CEA-dNLR score was superior to the single inflammatory biomarker to predict the survival of the disease, avoiding false-positive or false-negative result. However, several limitations of our study should be addressed. Firstly, only 220 eligible patients were included in our study, since small sample size might lead to unstable result. Secondary, this study was a retrospective design, all of the included patients were included from the two hospitals, and the conclusion was not validated by other centers. Thirdly, due to the incomplete survival data of the patient, we did not obtain sufficient progressionfree survival data, and it remained unknown the association between the score and progression of mGBC patient. For this, further large sample size and multi-center studies are warrant to confirm our result.
In conclusion, this study suggested that pretreatment pAlb, LMR, dNLR, and FPR were independent prognostic factors of mGBC patient and CEA-dNLR score was superior to these biomarkers to predict 3 years' clinical outcome of the patients.
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